NO20003694L - VLA-4 antagonister - Google Patents

VLA-4 antagonister

Info

Publication number
NO20003694L
NO20003694L NO20003694A NO20003694A NO20003694L NO 20003694 L NO20003694 L NO 20003694L NO 20003694 A NO20003694 A NO 20003694A NO 20003694 A NO20003694 A NO 20003694A NO 20003694 L NO20003694 L NO 20003694L
Authority
NO
Norway
Prior art keywords
vla
antagonists
inflammatory
useful
therapeutic
Prior art date
Application number
NO20003694A
Other languages
English (en)
Other versions
NO20003694D0 (no
Inventor
Sompong Wattansasin
Peter Josef Von Matt
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20003694D0 publication Critical patent/NO20003694D0/no
Publication of NO20003694L publication Critical patent/NO20003694L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/42—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Forbindelser med formel I og deres farmasøytisk akseptable salter er VLA-4-antagonister. De er nyttige ved hem- ming av celleadhesjon og ved den terapeutisk og profylaktiske behandlingen av Ln- fiammatoriske og autoimmune sykdommer, spesielt inflammatoriske luftveissykdom- mer. De er spesielt nyttige for å redusere post-kirurgisk inflammasjon, spesielt den som er et resultat av transplantasjonskirurgi.
NO20003694A 1998-01-23 2000-07-19 VLA-4 antagonister NO20003694L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1233698A 1998-01-23 1998-01-23
US11072398P 1998-12-03 1998-12-03
PCT/EP1999/000384 WO1999037605A1 (en) 1998-01-23 1999-01-21 Vla-4 antagonists

Publications (2)

Publication Number Publication Date
NO20003694D0 NO20003694D0 (no) 2000-07-19
NO20003694L true NO20003694L (no) 2000-09-20

Family

ID=26683440

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20003694A NO20003694L (no) 1998-01-23 2000-07-19 VLA-4 antagonister

Country Status (13)

Country Link
EP (1) EP1049665A1 (no)
JP (1) JP4564654B2 (no)
KR (1) KR20010034317A (no)
CN (1) CN1294576A (no)
AU (1) AU746174B2 (no)
BR (1) BR9907733A (no)
CA (1) CA2318639A1 (no)
EE (1) EE200000428A (no)
HU (1) HUP0100336A3 (no)
ID (1) ID26665A (no)
IL (1) IL137329A0 (no)
NO (1) NO20003694L (no)
WO (1) WO1999037605A1 (no)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2623900A (en) * 1999-01-22 2000-08-07 American Home Products Corporation Compounds which inhibit leukocyte adhesion mediated by vla-4
US6492372B1 (en) 1999-01-22 2002-12-10 Elan Pharmaceuticals, Inc. Heteroaryl, heterocyclic and aryl compounds which inhibit leukocyte adhesion mediated by VLA-4
US6436904B1 (en) 1999-01-25 2002-08-20 Elan Pharmaceuticals, Inc. Compounds which inhibit leukocyte adhesion mediated by VLA-4
CA2361162A1 (en) 1999-03-01 2000-09-08 Elan Pharmaceuticals, Inc. Alpha-aminoacetic acid derivatives useful as alpha 4 beta 7-receptor antagonists
WO2001042192A2 (en) * 1999-12-07 2001-06-14 Novartis Ag Vla-4 integrin antagonists
EA004673B1 (ru) 1999-12-28 2004-06-24 Пфайзер Продактс Инк. Непептидильные ингибиторы vla-4-зависимого связывания клеток, применяемые при лечении воспалительных, аутоимунных и респираторных заболеваний
DE10019755A1 (de) * 2000-04-20 2001-11-08 Bayer Ag Neue Aminoaryl/cycloalkylcarbonsäuren als Integrinantagonisten
GB2367816A (en) * 2000-10-09 2002-04-17 Bayer Ag Urea- and thiourea-containing derivatives of beta-amino acids
GB2369357A (en) * 2000-10-09 2002-05-29 Bayer Ag Aliphatic, cyclic amino carboxylic acids as integrin antagonists
GB2377933A (en) 2001-07-06 2003-01-29 Bayer Ag Succinic acid derivatives useful as integrin antagonists
TWI281470B (en) 2002-05-24 2007-05-21 Elan Pharm Inc Heterocyclic compounds which inhibit leukocyte adhesion mediated by alpha4 integrins
TW200307671A (en) 2002-05-24 2003-12-16 Elan Pharm Inc Heteroaryl compounds which inhibit leukocyte adhesion mediated by α 4 integrins
TW200610754A (en) * 2004-06-14 2006-04-01 Daiichi Seiyaku Co Vla-4 inhibitor
GB0523576D0 (en) * 2005-11-18 2005-12-28 Theradeas Ltd Drug composition and its use in therapy
KR20080100271A (ko) 2006-02-27 2008-11-14 엘란 파마슈티칼스, 인크. Ｖｌａ-4에 의해 매개되는 백혈구 부착을 억제하는 피리미디닐 술폰아미드 화합물
EP2510941A3 (en) 2007-02-20 2013-01-23 Merrimack Pharmaceuticals, Inc. Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonist
BRPI0911652A2 (pt) 2008-04-11 2015-08-04 Merrimack Pharmaceuticals Inc Ligantes de albumina sérica humana e seus conjugados

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6306840B1 (en) * 1995-01-23 2001-10-23 Biogen, Inc. Cell adhesion inhibitors
BR9814376A (pt) * 1997-12-23 2000-10-10 Aventis Pharma Ltd Composto ou um pró-medicamento correspondente, ou um sal farmaceuticamente aceitável ou solvato de um tal composto ou um pró-medicamento deste, uso destes, composição farmacêutica, processo para o tratamento de um paciente humano ou animal não humano sofrendo de, ou sujeito a, condições que podem ser melhoradas pela admnistração de um inibidor da adesão celular mediada por &4ß1, e, resina

Also Published As

Publication number Publication date
WO1999037605A1 (en) 1999-07-29
HUP0100336A2 (hu) 2001-07-30
ID26665A (id) 2001-01-25
KR20010034317A (ko) 2001-04-25
NO20003694D0 (no) 2000-07-19
EP1049665A1 (en) 2000-11-08
CA2318639A1 (en) 1999-07-29
JP4564654B2 (ja) 2010-10-20
JP2002501039A (ja) 2002-01-15
EE200000428A (et) 2001-12-17
AU746174B2 (en) 2002-04-18
IL137329A0 (en) 2001-07-24
AU2829299A (en) 1999-08-09
HUP0100336A3 (en) 2002-11-28
CN1294576A (zh) 2001-05-09
BR9907733A (pt) 2000-10-17

Similar Documents

Publication Publication Date Title
NO982731L (no) Antagonister av gonadotropinfrigivende hormon
DE60045508D1 (de) Dalda-analoge und ihre verwendung
JO2282B1 (en) Oxazole derivatives
NO20061454L (no) Compounds having CRTH2 antagonist activity
NO20062692L (no) Heterosykliske MEK inhibitorer og fremgangsmater for anvendelse derav
YU20999A (sh) Heterociklični derivati koji inhibiraju faktor xa
DE602004011394D1 (en) Thiazolderivate
NO20073465L (no) Benzotiazol-derivater
WO2005047244A3 (en) Inhibition of fgfr3 and treatment of multiple myeloma
CA2413424A1 (en) Substituted bicyclic derivatives for the treatment of abnormal cell growth
NO20031024D0 (no) Bicykliske pyrrolyl amider som glukogen fosforylase inhibitorer
NO20062704L (no) Azabicykliske heterocykler som cannabinoide reseptormodulatorer
IL158975A0 (en) 2-anilino-pyrimidine derivatives as cyclin dependent kinase inhibitors
NZ545506A (en) Therapeutic agents useful for treating pain
NO20021328L (no) Pyrazolopyrimidier som terapeutiske midler
DE60315674D1 (de) Neue imidazopyridine und ihre verwendung
UA49869C2 (uk) Нафтил-заміщені похідні бензимідазолу, фармацевтична композиція, спосіб лікування (варіанти) та спосіб інгібування людського фактора
NO20006157L (no) Celleadhesjons-inhiberende anti-inflammatoriske forbindelser
WO2001068586A3 (en) α4β1 AND α4β7 INTEGRIN INHIBITORS
BG106867A (en) Non-peptidyl inhibitors of vla-4 dependent cell binding useful in treating inflammatory autoimmune and respiratory diseases
NO991761L (no) Nye piperidin-kotokarbonsyre-derivater, deres fremstilling og anvendelse
ATE301654T1 (de) Naphthyridinderivate
BR9907733A (pt) Antagonistas vla-4
NO990433L (no) Nye forbindelser og blandinger for behandling av sykdommer i forbindelse med tryptase-aktivitet
NO954878L (no) Pyrrolderivater

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application